Zai Lab Ltd (ZLAB) ニュース

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today...

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 Positive China bridging study of KarXT...

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

First and only NMPA-approved treatment for patients with CIDP in China Third approval for efgartigimod franchise in China demonstrating Zai Lab’s...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

KarXT demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo...

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

-- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung...

Zai Lab Announces Participation in November and December Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following...

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Company to host conference call and webcast on October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT), following plenary oral presentation of data at...

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024

- Company to Host Conference Call and Webcast on November 12, 2024, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688...

Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Oral presentation during plenary session will discuss potential of ZL-1310 as an innovative ADC targeting Delta-like ligand 3 (DLL3), a validated...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities